Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 14/20 | 0.47 |
| ▸ | GUCY1A2 | P33402 | 14/20 | 0.47 |
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.47 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8561187 | 0.92 | KMT2A (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL11073074 | 0.86 | CYP3A4 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10532132 | 0.86 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL6356723 | 0.85 | CYP3A4 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8567739 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8562316 | 0.84 | HSD11B1 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15671387 | 0.83 | GUCY1B2 (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP3A4 | |
| SCHEMBL2191140 | 0.83 | MEN1 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2191580 | 0.82 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2189993 | 0.80 | ATP4A (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| WO-2018184976-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND USE OF SAME | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | WO | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3227287-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| EP-3004094-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015124544-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | WO | disclosed |
| WO-2014195333-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0033094-B1 | IMIDAZO(1,2-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| EP-0033094-A1 | Imidazo(1,2-a)pyridines, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | TNNI3, CYP11B2, PPIP5K2 | GUCY1B2 1819/4885GUCY1A2 876/4885GUCY1A1 1463/4885 |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | TNNI3, CYP11B2, PPIP5K2 | GUCY1B2 1819/4885GUCY1A2 876/4885GUCY1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.